IMTX Stock Overview
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States.
Notes are coming soon
Immatics N.V. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.34|
|52 Week High||US$13.60|
|52 Week Low||US$5.75|
|1 Month Change||-11.65%|
|3 Month Change||-20.11%|
|1 Year Change||-10.42%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-13.13%|
Recent News & Updates
Immatics launches $110M stock offeringOct 10
Cancer immunotherapy biotech Immatics up 18% on 4x normal volumeJul 19
Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn SituationJan 29
Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging HigherDec 16
Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent ResultsApr 01
What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?Jan 18
Immatics reports Q3 resultsDec 02
Immatics (IMTX) Investor Presentation - SlideshowNov 13
|IMTX||US Biotechs||US Market|
Return vs Industry: IMTX underperformed the US Biotechs industry which returned 4.4% over the past year.
Return vs Market: IMTX matched the US Market which returned -9.6% over the past year.
|IMTX Average Weekly Movement||7.3%|
|Biotechs Industry Average Movement||12.1%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||17.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: IMTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: IMTX's weekly volatility (7%) has been stable over the past year.
About the Company
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell.
Immatics N.V. Fundamentals Summary
|IMTX fundamental statistics|
Is IMTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IMTX income statement (TTM)|
|Cost of Revenue||€101.89m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.45|
|Net Profit Margin||22.50%|
How did IMTX perform over the long term?See historical performance and comparison